$320.15
3.571.13%
最終更新: Oct 19, 9:30 AM
$320.15
3.571.13%
Benzinga
Benzinga
Benzinga
月曜日, 10 19
Benzinga
© 2026 Benzinga | All Rights Reserved
Krystal Biotech (KRYS) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $1.89 | $1.43 | $1.61 | $1.12 |
| Actual | $1.79 | $1.83 | $1.70 | $2.66 |
| Surprise | -5.29% | +28.0% | +5.59% | +137.5% |
| Revenue | ||||
| Estimate | $122.8M | $112.1M | $106.5M | $92.7M |
| Actual | $119.2M | $116.4M | $107.1M | $97.8M |
| Surprise | -2.95% | +3.76% | +0.55% | +5.56% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $1.92 | $2.03 | $2.37 | $2.20 |
| Revenue | ||||
| Consensus | $126.7M | $134.4M | — | — |
| 会計四半期 | 報告日 | 実質EPS | 推定EPS | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 3, 2026 | $1.79 | $1.89 | -5.29 % |
| Q1 | May 4, 2026 | $1.83 | $1.43 | 28.0 % |
| Q4 | Feb 17, 2026 | $1.70 | $1.61 | 5.59 % |
| Q3 | Nov 3, 2025 | $2.66 | $1.12 | 137.5 % |
| 会計四半期 | 報告日 | 実際の収益 | 推定収益 | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 3, 2026 | $119.22M | $122.85M | -2.95 % |
| Q1 | May 4, 2026 | $116.36M | $112.14M | 3.76 % |
| Q4 | Feb 17, 2026 | $107.11M | $106.52M | 0.55 % |
| Q3 | Nov 3, 2025 | $97.80M | $92.65M | 5.56 % |